Clade Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Clade Therapeutics, founded in Cambridge, Massachusetts in 2021 by Chad Cowan, developed off-the-shelf cell therapies from induced pluripotent stem cells. Its platform immune-cloaked iPSCs and differentiated them into therapeutic cells, aiming for scalable, consistent medicines for cancer and autoimmune disease. The company launched with an $87 million Series A led by Syncona in November 2021, acquired Dutch gamma-delta TCR company Gadeta in 2023, and was itself acquired by Century Therapeutics in April 2024.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Chad Cowan founds Clade Therapeutics; it launches with an $87 million Series A led by Syncona.
- Acquisition
Clade acquires Gadeta, a Dutch gamma-delta T-cell receptor company, in October 2023.
- Acquisition
Century Therapeutics acquires Clade on April 11, 2024 for $35 million upfront plus up to $10 million in milestones.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.